Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects total U.S. net product sales for the fourth quarter of 2025 to be ...

In December 2025, Palvella requested a Preliminary Breakthrough Therapy Designation Advice meeting with the FDA which is anticipated for the first quarter of 2026. The Company plans to commence a ...

Ltd. to Further Strengthen DSA Supply Chain; Transaction Expected to be Accretive to Non-GAAP Earnings Per Share by Approximately $0.25 in 2026 and Approximately $0.60 in 2027 –– Exercises Option to ...

Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in ...

For the fiscal year ending January 31, 2027, management expects revenues in the range of $1.38 billion to $1.41 billion with Adjusted EBITDA margin of 43.8% to 44.3% and a yield on HSA Cash of ...

Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year ...

The Oncology Institute, Inc. (NASDAQ: TOI) ('TOI” or the 'Company”), one of the largest value-based oncology groups in the ...

Homeless shelters across the state received funding to keep people warm amid a statewide cold snap thanks to a first-ever, ...

While drought conditions improved during the summer, a dry fall left much of Iowa with abnormally dry or moderate drought ...

On February 4-in Las Vegas, at the National Automobile Dealers Association (NADA) Show - FF will hold a final launch of its ...

Over his nearly 50-year career, Burbank-based attorney Dennis Block has built a reputation as a staunch advocate for Southern ...

First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries - Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) ...